相关实验视频

Updated: Jan 9, 2026

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

托巴比他抑制了乳腺癌的增殖,通过降低增殖细胞核抗原的下调

X Q Teng^1,2, Y Q Sun^1,2, X R Liu^1,2

¹Department of Anesthesiology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210028, China.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society

|December 3, 2025

概括

巴比他 (PB) 通过降低增殖细胞核抗原 (PCNA) 水平来抑制乳腺癌细胞的生长. 这项研究表明PB PB.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
细胞生物学细胞生物学

背景情况:

巴尔比他 (PB) 是一种巴比酸麻醉剂,具有成熟的临床用途.
它的潜在抗癌特性,特别是在乳腺癌中,在很大程度上是未被探索的.
了解PB的细胞机制对于潜在的治疗应用至关重要.

研究的目的:

为了研究Pentobarbital (PB) 对乳腺癌细胞增殖的抑制作用.
阐明增殖细胞核抗原 (PCNA) 在PB介导的抗癌作用中的作用.
探索PB作为乳腺癌治疗中的新型治疗剂的潜力.

主要方法:

利用乳腺癌细胞系 (MDA-MB-231,MCF-7) 来评估PB对增殖的影响.
采用甲基 thiazolyl tetrazolium (MTT),殖民地形成,和氧化 (BrdU) 的测定用于扩散的测量.
通过Western blot和RT-PCR分析PCNA和细胞周期基因的蛋白质和mRNA表达,包括过度表达和淘汰模型.

主要成果:

巴比他 (PB) 显著抑制了乳腺癌细胞的增殖,并调节了与细胞周期相关的基因.
PB治疗导致增殖细胞核抗原 (PCNA) 表达的下调.
PCNA过度表达增强了增殖,而PCNA倒置抑制了它,PCNA过度表达部分挽救了PB的抑制作用.

结论:

巴比他 (PB) 抑制乳腺癌的扩散,部分是通过降低PCNA的调节.
PB显示出作为抗癌剂的潜力,提供新的治疗途径.
对PB抗癌机制的进一步研究可以支持其在瘤学中的临床应用.

关键词:

乳腺癌细胞系的细胞系.环 D1 D1 的时间.环 E1 E1 环 E1 环多巴比塔尔 (pentobarbital) 是一种药物.增殖细胞核抗原的核抗原.它们的扩散和扩散.蛋白质 21 蛋白质 21

更多相关视频

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...